supp.ai
Discover Supplement-Drug Interactions
Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago
Research Papers that Mention the Interaction
“In a randomized phase II trial in patients (pts) with advanced NSCLC, the vascular disrupting agent ASA404 (vadimezan) in combination with CP was found to improve several efficacy parameters including overall survival (OS).”
“The addition of ASA404 to CP , although generally well-tolerated, failed to improve efficacy in pts with advanced NSCLC.”
Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP) with or without the vascular-disrupting agent vadimezan (ASA404) in advanced non-small cell lung cancer (NSCLC).
Help us improve supp.ai, we'd love to hear your feedback: Submit Feedback